Teriparatide vs abaloparatide: evidence, cost, and legality

Which is better, teriparatide or abaloparatide?

Both carry the top evidence grade and full FDA approval. In ACTIVE, new vertebral fractures were 0.58% with abaloparatide and 0.84% with teriparatide versus 4.22% with placebo, but the teriparatide arm was open label and the trial was not designed to prove one better than the other, while hypercalcemia was clearly less common with abaloparatide. Teriparatide has more indications (men, glucocorticoid induced osteoporosis) and generic pricing, and VERO showed it prevents more vertebral fractures than oral risedronate. Insurance coverage, calcium tolerance, and indication usually decide. [1] [2] [3] [5] [6]

How do teriparatide and abaloparatide compare?

Teriparatide and Abaloparatide compared by dimension
Dimension	Teriparatide	Abaloparatide
Molecule and mechanism [5] [6]	Recombinant human PTH (1-34); daily pulses activate the PTH1 receptor to favor bone formation over resorption.	Synthetic PTHrP (1-34) analog that preferentially binds the transient RG conformation of the PTH1 receptor, giving a shorter signal with less resorption and calcium rise.
Pivotal placebo controlled result [1] [3]	Neer 2001 (1,637 women, median 21 months): new vertebral fractures 5% versus 14% placebo (relative risk 0.35); nonvertebral fragility fractures 3% versus 6%; lumbar spine BMD up 9%.	ACTIVE (2,463 women, 18 months): new vertebral fractures 0.58% versus 4.22% placebo (86% relative reduction); nonvertebral fractures hazard ratio 0.57; lumbar spine BMD up 11.2%.
Note: The trials enrolled different populations over different periods, so absolute fracture rates are not directly comparable.
Active comparator evidence [2] [4]	VERO: new vertebral fractures 5.4% versus 12.0% with oral risedronate over 24 months (risk ratio 0.44) in severe osteoporosis.	ACTIVExtend: 18 months of abaloparatide followed by alendronate kept an 87% vertebral fracture reduction versus placebo followed by alendronate.
Hypercalcemia [1] [3]	6.4% in the open label teriparatide arm of ACTIVE; 11% versus 2% placebo in Neer 2001 (usually mild).	3.4% in ACTIVE, about half the teriparatide rate.
Other common side effects [1] [6]	Dizziness (9% versus 6%), leg cramps, nausea, headache, and orthostatic hypotension with the first doses.	Dizziness (10%), nausea (8%), headache (8%), palpitations (5%), and orthostatic hypotension within 4 hours of injection.
FDA indications [5] [6]	Postmenopausal osteoporosis at high fracture risk, primary or hypogonadal osteoporosis in men, and glucocorticoid induced osteoporosis (Forteo, 2002; generic and 505(b)(2) products since).	Postmenopausal osteoporosis at high fracture risk (Tymlos, 2017) and osteoporosis in men (2022).
Label dose and duration [5] [6]	20 mcg subcutaneously once daily in the thigh or abdomen; the label says use beyond 2 years in a lifetime should be considered only if fracture risk remains high (the osteosarcoma boxed warning was removed in 2020).	80 mcg subcutaneously once daily in the periumbilical abdomen; the label notes safety and efficacy were not evaluated beyond 2 years (the boxed warning was removed in 2021).
Cost [5] [6]	Brand Forteo roughly 3,000 to 4,000 USD per month at list; generic and 505(b)(2) versions roughly 1,000 to 2,000 USD.	Roughly 2,000 to 3,000 USD per month at list; no generic; manufacturer copay program for commercially insured patients.
Note: Both usually require prior authorization documenting high fracture risk.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Teriparatide and Abaloparatide: grade, status, and cost
Attribute	Teriparatide	Abaloparatide
Class	Recombinant fragment of human parathyroid hormone (amino acids 1 to 34), a bone anabolic agent	Synthetic 34 amino acid analog of parathyroid hormone related protein (PTHrP), a bone anabolic agent
What it is	FDA approved daily osteoporosis injection that cut new spine fractures by 65% in its pivotal trial and beat risedronate head to head.	FDA approved daily osteoporosis injection that cut new spine fractures by 86% versus placebo (a dummy injection) in the 2,463 patient ACTIVE trial.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved as Forteo in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and glucocorticoid induced osteoporosis. A 505(b)(2) product (Bonsity, 2019) and generic teriparatide injections have since been approved. In November 2020 FDA approved label changes removing the boxed warning for osteosarcoma and the 2 year lifetime treatment limit. Because approved products exist, compounding teriparatide is not permitted except in narrow patient specific circumstances.	FDA approved as Tymlos in April 2017 for postmenopausal women with osteoporosis at high risk of fracture, with an expanded indication for men with osteoporosis in December 2022. In December 2021 FDA approved removal of the boxed warning for osteosarcoma and the 2 year cumulative use limit. Because an approved product exists, compounding is not permitted except for a documented patient specific need. No generic is available as of the last verified date.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection once daily (prefilled pen)	Subcutaneous injection once daily (prefilled pen)
Typical cost	Brand Forteo has a manufacturer list price of 4,289.89 USD per pen, and one pen is a 28 day supply. Generic teriparatide pens cost about 1,036 to 1,146 USD with a discount card at the lowest-priced pharmacies, against average retail prices of about 2,977 to 3,214 USD (checked 2026-09-22). The Forteo savings card can bring a covered commercial prescription to 4 USD a month. Medicare Part D and most commercial plans cover it with prior authorization for high fracture risk.	List price roughly 2,000 to 3,000 USD per month. Most commercial plans and Medicare Part D cover it with prior authorization; a manufacturer copay program is available for commercially insured patients.
Last verified	Sep 23, 2026	Sep 23, 2026

Has teriparatide been tested directly against abaloparatide?

Direct comparisons of Teriparatide and Abaloparatide
Study	Design and population	Outcome	Grade
Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE)2016 PMID 27533157	Randomized, double blind, placebo controlled trial with an open label teriparatide arm, 18 monthsn = 2,463 Postmenopausal women with osteoporosis	New vertebral fractures 0.58% with abaloparatide, 0.84% with open label teriparatide, and 4.22% with placebo; hypercalcemia 3.4% with abaloparatide versus 6.4% with teriparatide	Evidence: Human RCT evidence

What do teriparatide and abaloparatide cost?

Typical cost of Teriparatide and Abaloparatide
Dimension	Teriparatide	Abaloparatide
Typical cost	Brand Forteo has a manufacturer list price of 4,289.89 USD per pen, and one pen is a 28 day supply. Generic teriparatide pens cost about 1,036 to 1,146 USD with a discount card at the lowest-priced pharmacies, against average retail prices of about 2,977 to 3,214 USD (checked 2026-09-22). The Forteo savings card can bring a covered commercial prescription to 4 USD a month. Medicare Part D and most commercial plans cover it with prior authorization for high fracture risk.	List price roughly 2,000 to 3,000 USD per month. Most commercial plans and Medicare Part D cover it with prior authorization; a manufacturer copay program is available for commercially insured patients.
Price detail	Teriparatide price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is abaloparatide better than teriparatide?

It has not been proven better at preventing fractures. In ACTIVE, vertebral fractures were 0.58% with abaloparatide and 0.84% with open label teriparatide, both far below placebo, but the trial was not designed to test superiority between the two. Abaloparatide did cause hypercalcemia about half as often. [3]

Which one is cheaper?

Teriparatide, because generic and 505(b)(2) versions are available at roughly 1,000 to 2,000 USD per month at list, compared with roughly 2,000 to 3,000 USD for abaloparatide, which has no generic. Actual cost depends mostly on insurance coverage and prior authorization. [5] [6]

Can either be used in men or with steroid induced osteoporosis?

Both are approved for men with osteoporosis. Only teriparatide carries an FDA indication for glucocorticoid induced osteoporosis. [5] [6]

Is there still a 2 year limit?

No. FDA removed the osteosarcoma boxed warning and the 2 year cumulative limit for teriparatide in 2020 and for abaloparatide in 2021, based on the absence of a human osteosarcoma signal. Longer use is now a clinical decision for patients who remain at high fracture risk. [5] [6]

What happens after treatment stops?

Bone gained on either drug is usually preserved by switching to an antiresorptive. ACTIVExtend showed that following abaloparatide with alendronate kept an 87% vertebral fracture reduction versus placebo followed by alendronate. [4] [6]

Are they allowed in sport?

Neither teriparatide nor abaloparatide is on the WADA Prohibited List, though athletes should confirm against the current list and any therapeutic use rules. [7]

Conditions studied

Osteoporosis

From the blog

Peptides for women, ranked by human evidence
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 23). Teriparatide vs abaloparatide: evidence, cost, and legality. https://peptideagent.ai/compare/teriparatide-vs-abaloparatide
HTML link: <a href="https://peptideagent.ai/compare/teriparatide-vs-abaloparatide">Teriparatide vs abaloparatide: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.

Teriparatide vs abaloparatide

The short answer